In addition, the pooled results based on three studies indicated that there was a significant increase in the proportion of patients who were able to reduce or discontinue their concurrent ITP therapies in the TPO-RA group compared with the control group (RR: 1.85, 95% CI: 1.13–3.01, P = 0.014 Fig. 4b). The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.